Pear Therapeutics said this month that it closed a $64 million Series C round led by Temasek.
The Boston-based company plans to use its newly-acquired funds to support the global commercialization of its reSET prescription digital therapeutics and fund its clinical pipeline, as well as buy up additional assets.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.